Sponsors

Evident and Ultivue collaborate to advance multiplex slide imaging

Life science imaging systems manufacturer Evident Corporation and Ultivue, an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, have announced a collaborative agreement to promote whole slide imaging using multiplexed immunofluorescence (mIF) assays to advance translational research in the Americas.

Combining Ultivue’s mIF assays with the Olympus SLIDEVIEW VS200 research slide scanner provides a convenient, fast tool for whole slide mIF imaging in translational studies for researchers in academia, biotech, pharma and contract research organisations in the Americas. The collaboration builds on the existing partnership between the two firms to meet the scientific community’s increasing need for fluorescent multiplexing.

Ultivue develops unique solutions for mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex technology enabling improved signal-to-noise data is designed for fast and comprehensive exploration of up to 12 biologically relevant targets in one tissue slide, with same-slide haematoxylin and eosin (H&E) analysis in tissue samples. This technology combines the power of computational pathology and spatial biology to guide translational science in immuno-oncology.

Evident Corporation, a wholly owned subsidiary of Olympus Corporation, manufacturers leading-edge life science microscopes that support a broad range of academic and clinical research areas, pathology diagnostic services and the growing demand for novel drug discovery. The Olympus VS200 slide scanner has advanced the field of whole slide imaging with high-quality optics, fast scanning and flexible imaging options that include a robust solution for fluorescent multiplexing.

“We are excited to enhance our relationship with Evident to further optimise the integration of Ultivue assays on the SLIDEVIEW VS200 research slide scanner. We jointly enable highly efficient workflows to drive adoption of tissue multiplexing on larger cohorts,” said Florian Leiss, PhD, the Vice President of Product Strategy and Corporate Development at Ultivue.

Latest Issues

BSMT 40th Anniversary Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Transforming Digital Pathology & AI: The Path Forward

Royal College Of Physicians Of Edinburgh
15 May, 2025

The 10 Year Plan - Clinical Innovations Expo

Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025